Metabolic Reprogramming of Recruited Alveolar Macrophages by Arginine In Acute Lung Injury

急性肺损伤中精氨酸对募集的肺泡巨噬细胞的代谢重编程

基本信息

  • 批准号:
    10377415
  • 负责人:
  • 金额:
    $ 15.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-04-09 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Project Summary: This proposal describes a five-year training program that will ultimately develop Dr. Kara Mould into an independent academic basic science investigator. Her long-term career goal is to advance the field of macrophage biology through the elucidation of targets for lung repair and the treatment of patients with the acute respiratory distress syndrome or inflammatory lung diseases. During this K08 Award, Dr. Mould will gain specific career development training and mentorship closely aligned with an innovative research plan. She proposes to study the affect of arginine metabolism on alveolar macrophage programming in models of acute lung injury. Given its applicability to multiple pulmonary disorders and potential applicability to repair of injury in other organs, this work is directly relevant to the NHLBI. Candidate: Dr. Mould is a board-certified Pulmonary and Critical Care Medicine physician at the University of Colorado School of Medicine. She is in the final year of fellowship training, having elected to complete an optional year of dedicated research. Her previous record of academic excellence, basic science research, and scientific publications demonstrates a firm commitment to a career as an academic clinician-scientist. Training: The proposed career development plan augments Dr. Mould's prior mentored research during her undergraduate, medical, residency, and fellowship training. She proposes to meet her short-term objectives through an integrated combination of intensive mentoring by internationally renowned experts in macrophage biology and didactic and hands-on experiences in (i) Immunology, (ii) metabolic programming of immune cells (iii) bioinformatics, (iv) scientific writing and presentation, and (v) laboratory leadership. Mentors/Environment: Dr. Mould has established close working relationships with highly experienced mentors and collaborators who contribute expertise in macrophage and lung biology (Drs. Henson and Janssen), metabolomics (Dr. D'Alessandro), bioinformatics (Dr. Fingerlin), human lung and epithelial biology (Dr. Mason), endothelial biology (Dr. Petrache), and career development of clinician-scientists (Drs. Douglas, Eickelberg, and Voelker.) The proposed activities will be based at National Jewish Health with support from the University of Colorado, both renowned respiratory medical centers and world-class research institutions. Research Project: The primary objective of this proposal is to identify the mechanism by which alveolar macrophages are programmed to resolve inflammation and promote repair of the injured lung. Specifically, our study will test the hypothesis that the metabolic enzyme, arginase 1, is a critical checkpoint for both inflammatory and reparative programming of alveolar macrophages. This will be tested using a well- established murine model of lung injury and primary cells isolated from diseased human lungs or non-diseased controls. In doing so, the specific contribution of arginine metabolism to macrophage programming and pathways that regulate recovery from inflammatory lung diseases will be elucidated.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kara J Mould其他文献

Kara J Mould的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kara J Mould', 18)}}的其他基金

Metabolic Reprogramming of Recruited Alveolar Macrophages by Arginine In Acute Lung Injury
急性肺损伤中精氨酸对募集的肺泡巨噬细胞的代谢重编程
  • 批准号:
    10191011
  • 财政年份:
    2018
  • 资助金额:
    $ 15.96万
  • 项目类别:
Metabolic Reprogramming of Recruited Alveolar Macrophages by Arginine In Acute Lung Injury
急性肺损伤中精氨酸对募集的肺泡巨噬细胞的代谢重编程
  • 批准号:
    9886259
  • 财政年份:
    2018
  • 资助金额:
    $ 15.96万
  • 项目类别:

相似海外基金

Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.96万
  • 项目类别:
    Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
  • 批准号:
    10722669
  • 财政年份:
    2023
  • 资助金额:
    $ 15.96万
  • 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
  • 批准号:
    491387
  • 财政年份:
    2023
  • 资助金额:
    $ 15.96万
  • 项目类别:
    Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
  • 批准号:
    10678788
  • 财政年份:
    2023
  • 资助金额:
    $ 15.96万
  • 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
  • 批准号:
    10646578
  • 财政年份:
    2023
  • 资助金额:
    $ 15.96万
  • 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
  • 批准号:
    23K08447
  • 财政年份:
    2023
  • 资助金额:
    $ 15.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
  • 批准号:
    10601865
  • 财政年份:
    2023
  • 资助金额:
    $ 15.96万
  • 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
  • 批准号:
    23K08360
  • 财政年份:
    2023
  • 资助金额:
    $ 15.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
  • 批准号:
    10722194
  • 财政年份:
    2023
  • 资助金额:
    $ 15.96万
  • 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
  • 批准号:
    10594793
  • 财政年份:
    2023
  • 资助金额:
    $ 15.96万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了